Clinical Trials
Low and Intermediate Risk Prostate Cancer

This Information is provided to help patients identify clinical trials for educational purposes and not to recruit patients for any specific trials. Patients should consult with their personal doctor and the trial sponsors for additional information on trials of interest.

Determine the rates of acute and late grade 3 or higher gastrointestinal and genitourinary toxicity observed and estimate the rate of biochemical Disease-Free Survival

Number: NCT00977860
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Pittsburgh
Sponsor Trial Information
Trial Location(s) and Contact(s)
A study to evaluate the use of moderate hypofractionated proton therapy in low and intermediate risk prostate cancer patients

Number: NCT02040610
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Provision Center for Proton Therapy|Center for Biomedical Research, LLC
Sponsor Trial Information
Trial Location(s) and Contact(s)
Evaluate the response of the cancer and side effects of radiation to pelvic lymph nodes and to the prostate

Number: NCT02177292
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Medical College of Wisconsin
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study Evaluating Brachytherapy For Patients With Low Risk Prostate Cancer

Number: NCT02290366
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Ronald M. Benoit, MD|University of Pittsburgh
Sponsor Trial Information
Trial Location(s) and Contact(s)
Diet and Exercise Program to Promote Weight Loss and Improve Health in Men With Low- or Low-Intermediate-Risk Prostate Cancer

Number: NCT02454517
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
PSA-targeted Immunotherapy Treatment With or Without Ipilimumab for Prostate Cancer

Number: NCT02506114
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of California, San Francisco
Sponsor Trial Information
Trial Location(s) and Contact(s)
Apalutamide in Treating Patients With Prostate Cancer Who Are in Active Surveillance

Number: NCT02721979
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Washington|Janssen Scientific Affairs, LLC|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Evaluate the effectiveness of ProstAtak® immunotherapy in patients undergoing active surveillance for localized prostate cancer

Number: NCT02768363
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Advantagene, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study the effectiveness of one combination of drugs compared to another combination of drugs before surgery to see if this will improve surgical outcomes and reduce or eliminate Prostate Cancer

Number: NCT02903368
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Dana-Farber Cancer Institute|Janssen Scientific Affairs, LLC
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of adding abiraterone acetate and prednisone to the combination of apalutamide and a standard type of drug can help to control prostate cancer when given before surgery

Number: NCT03279250
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): M.D. Anderson Cancer Center|Janssen Scientific Affairs, LLC
Sponsor Trial Information
Trial Location(s) and Contact(s)
Specialized radiation therapy for Treating Patients With Prostate Cancer

Number: NCT03367702
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): NRG Oncology|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
To learn more about the outcomes and early and late side effects of treating early stage prostate cancer with high dose rate brachytherapy

Number: NCT03424850
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Washington University School of Medicine
Sponsor Trial Information
Trial Location(s) and Contact(s)
To evaluate whether olaparib can reduce prostate cancer with defects in DNA repair genes when olaparib is given for approximately 3 months before surgery

Number: NCT03432897
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Dr Anthony Mega|Rhode Island Hospital|The Miriam Hospital|AstraZeneca|Brown University
Sponsor Trial Information
Trial Location(s) and Contact(s)
To compare the decline in patient health-related quality of life (HRQOL) instrument-defined erectile dysfunction following stereotactic ablative body radiotherapy (SAbR) with or without neurovascular sparing

Number: NCT03525262
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Texas Southwestern Medical Center
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of Rucaparib in Nonmetastatic Prostate Cancer Patients with Genetic Mutations

Number: NCT03533946
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Utah|Clovis Oncology, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of Chemotherapy for Prostate Cancer With PSA-only Recurrence

Number: NCT03572387
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Icahn School of Medicine at Mount Sinai
Sponsor Trial Information
Trial Location(s) and Contact(s)




PHEN,Inc. © 2018 All rights reserved